Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis?
Rudge
Peter
P
National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. peter.rudge@uclh.org
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000906:Antibodies / Q000097:blood; D006801:Humans; D016899:Interferon-beta / Q000276:immunology* / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology*; D055502:Secondary Prevention
D000276:Adjuvants, Immunologic; D000906:Antibodies; D016899:Interferon-beta